MOCS3: A Gene Linked To Disease and Potential Drug Target (G27304)

Target Name: MOCS3

NCBI ID: G27304

MOCS3

MOCS3: A Gene Linked To Disease and Potential Drug Target

MOCS3 (MutL homolog 3) is a gene that encodes a protein known as UBA4 (Ubiquitin-proteasome adaptor 4). UBA4 plays a critical role in the regulation of protein degradation, which is a process that is essential for maintaining cellular homeostasis. Mutations in the MOCS3 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, MOCS3 has become an attractive target for researchers to study and potentially develop as a drug or biomarker.

The protein encoded by the MOCS3 gene is composed of 19 amino acid residues and has a calculated molecular weight of 20 kDa. It belongs to the superfamily of ubiquitin-proteasome adaptor proteins, which are characterized by their ability to interact with various protein substrates and participate in the ubiquitin-proteasome system. This system is responsible for the degradation of damaged or dysfunctional proteins, which is essential for maintaining cellular homeostasis.

Mutations in the MOCS3 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that MOCS3 mutations are associated with an increased risk of colorectal cancer and with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Additionally, MOCS3 mutations have also been implicated in autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.

In addition to its potential role in disease, MOCS3 also has potential as a drug or biomarker. Studies have shown that MOCS3 interacts with a variety of protein substrates and has been shown to play a role in the regulation of protein degradation. As a result, MOCS3 may be a potential drug or biomarker target in diseases that are characterized by the over-expression or dysfunction of protein substrates.

In conclusion, MOCS3 is a gene that encodes a protein that plays a critical role in the regulation of protein degradation. Mutations in the MOCS3 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, MOCS3 has become an attractive target for researchers to study and potentially develop as a drug or biomarker. Further research is needed to fully understand the role of MOCS3 in disease and to develop effective treatments.

Protein Name: Molybdenum Cofactor Synthesis 3

Functions: Plays a central role in 2-thiolation of mcm(5)S(2)U at tRNA wobble positions of cytosolic tRNA(Lys), tRNA(Glu) and tRNA(Gln). Also essential during biosynthesis of the molybdenum cofactor. Acts by mediating the C-terminal thiocarboxylation of sulfur carriers URM1 and MOCS2A. Its N-terminus first activates URM1 and MOCS2A as acyl-adenylates (-COAMP), then the persulfide sulfur on the catalytic cysteine is transferred to URM1 and MOCS2A to form thiocarboxylation (-COSH) of their C-terminus. The reaction probably involves hydrogen sulfide that is generated from the persulfide intermediate and that acts as nucleophile towards URM1 and MOCS2A. Subsequently, a transient disulfide bond is formed. Does not use thiosulfate as sulfur donor; NFS1 probably acting as a sulfur donor for thiocarboxylation reactions

The "MOCS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MOCS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets